Erratum: Ovarian cancer cell line panel (OCCP): Clinical importance of in vitro morphological subtypes (PLoS ONE (2014) 9:9 (e103988) DOI: 10.1371/journal.pone.0103988);Ovarian cancer cell line panel (OCCP): Clinical importance of in vitro morphological subtypes

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Beaufort, Corine M ^a   Helmijr, Jean C A ^a   Piskorz, Anna M ^c   Hoogstraat, Marlous ^d   Ruigrok Ritstier, Kirsten ^a   Besselink, Nicolle ^d   Murtaza, Muhammed ^c   Van IJcken, Wilfred F J ^b   Heine, Anouk A J ^a   Smid, Marcel ^a   Koudijs, Marco J ^d   Brenton, James D ^c   Berns, Els M J J ^a   Helleman, Jozien ^a  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; GEMCITABINE; MESSENGER RNA; MICRORNA; OXALIPLATIN; PACLITAXEL;

2774 CELL LINE; 59M CELL LINE; A2780 CELL LINE; A2780ADR CELL LINE; A2780CIS CELL LINE; ARTICLE; CAOV3 CELL LINE; CAOV4 CELL LINE; CELL MIGRATION; CELL MOTION; CELL STRUCTURE; CONTROLLED STUDY; COV318 CELL LINE; COV362 CELL LINE; COV362.4 CELL LINE; COV413A CELL LINE; COV413B CELL LINE; COV504 CELL LINE; COV644 CELL LINE; DRUG RESPONSE; ES2 CELL LINE; EXON; FEMALE; GENE EXPRESSION PROFILING; GENE MUTATION; HOC7 CELL LINE; HUMAN; HUMAN CELL; IGROV1 CELL LINE; IN VITRO STUDY; METASTASIS; NUCLEOTIDE SEQUENCE; OAW28 CELL LINE; OAW42 CELL LINE; OV17R CELL LINE; OV56 CELL LINE; OV7 CELL LINE; OV90 CELL LINE; OVARIAN CANCER CELL LINE; OVARY CANCER; OVCAR3 CELL LINE; PEA1 CELL LINE; PEA2 CELL LINE; PEO1 CELL LINE; PEO14 CELL LINE; PEO16 CELL LINE; PEO23 CELL LINE; PEO4 CELL LINE; SKOV3 CELL LINE; SKOV6 CELL LINE; TOV112D CELL LINE; TOV21G CELL LINE; UWB1.289 CELL LINE; UWB1.289+BRCA1 CELL LINE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NEOPLASM; OVARY TUMOR; PATHOLOGY;

FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS;

EID: 84907197654     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0122284     Document Type: Erratum

References (90)

1. Bookman MA (2011) First line therapy: have we made any improvement? Eur J Cancer 47 Suppl 3: S93-103
2. Banerjee S, Kaye S (2011) The role of targeted therapy in ovarian cancer. Eur J Cancer 47 Suppl 3: S116-130
3. Vaughan S, Coward JI, Bast RC Jr, Berchuck A, Berek JS, et al. (2011) Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer 11: 719-725
4. Cancer Genome Atlas Research N (2011) Integrated genomic analyses of ovarian carcinoma. Nature 474: 609-615
5. Berns EM, Bowtell DD (2012) The changing view of high-grade serous ovarian cancer. Cancer Res 72: 2701-2704
6. Ahmed AA, Etemadmoghadam D, Temple J, Lynch AG, Riad M, et al. (2010) Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol 221: 49-56
7. Kurman RJ, Shih Ie M (2008) Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications. Int J Gynecol Pathol 27: 151-160
8. Landen CN Jr, Birrer MJ, Sood AK (2008) Early events in the pathogenesis of epithelial ovarian cancer. J Clin Oncol 26: 995-1005
9. Institute TS COSMIC Catalogue of somatic mutations in cancer (vs 57). version 57 ed
10. The Cancer Genome Atlas Research N, Genome sequencing centres: Broad I, Hammerman PS, Lawrence MS, Voet D, et al. (2012) Comprehensive genomic characterization of squamous cell lung cancers. Nature
11. Tothill RW, Tinker AV, George J, Brown R, Fox SB, et al. (2008) Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res 14: 5198-5208
12. Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A, et al. (2012) Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483: 570-575
13. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, et al. (2012) The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483: 603-607
14. Marcotte R, Brown KR, Suarez F, Sayad A, Karamboulas K, et al. (2012) Essential gene profiles in breast, pancreatic, and ovarian cancer cells. Cancer Discov 2: 172-189
15. Itamochi H, Yoshida T, Walker CL, Bartholomeusz C, Aoki D, et al. (2011) Novel mechanism of reduced proliferation in ovarian clear cell carcinoma cells: cytoplasmic sequestration of CDK2 by p27. Gynecol Oncol 122: 641-647
16. Sheppard KE, Cullinane C, Hannan KM, Wall M, Chan J, et al. (2013) Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors. Eur J Cancer 49: 3936-3944
17. Young JL, Koon EC, Kwong J, Welch WR, Muto MG, et al. (2011) Differential hRad17 expression by histologic subtype of ovarian cancer. J Ovarian Res 4: 6
18. Helleman J, Jansen MP, Span PN, van Staveren IL, Massuger LF, et al. (2006) Molecular profiling of platinum resistant ovarian cancer. Int J Cancer 118: 1963-1971
19. Mestdagh P, Van Vlierberghe P, De Weer A, Muth D, Westermann F, et al. (2009) A novel and universal method for microRNA RT-qPCR data normalization. Genome Biol 10: R64
20. Ramirez-Ardila DE, Helmijr JC, Look MP, Lurkin I, Ruigrok-Ritstier K, et al. (2013) Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen. Breast Cancer Res Treat 139: 39-49
21. Kompier LC, Lurkin I, van der Aa MN, van Rhijn BW, van der Kwast TH, et al. (2010) FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy. PLoS One 5: e13821
22. Lurkin I, Stoehr R, Hurst CD, van Tilborg AA, Knowles MA, et al. (2010) Two multiplex assays that simultaneously identify 22 possible mutation sites in the KRAS, BRAF, NRAS and PIK3CA genes. PLoS One 5: e8802
23. Harakalova M, Mokry M, Hrdlickova B, Renkens I, Duran K, et al. (2011) Multiplexed array-based and in-solution genomic enrichment for flexible and cost-effective targeted next-generation sequencing. Nat Protoc 6: 1870-1886
24. Nijman IJ, Mokry M, van Boxtel R, Toonen P, de Bruijn E, et al. (2010) Mutation discovery by targeted genomic enrichment of multiplexed barcoded samples. Nat Methods 7: 913-915
25. Iglewicz B, Hoaglin D (1993) How to Detect and Handle Outliers. Milwaukee, Wis: ASQC Quality Press
26. Forshew T, Murtaza M, Parkinson C, Gale D, Tsui DW, et al. (2012) Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med 4: 136ra168
27. Robinson JT, Thorvaldsdottir H, Winckler W, Guttman M, Lander ES, et al. (2011) Integrative genomics viewer. Nat Biotechnol 29: 24-26
28. Sieuwerts AM, Kraan J, Bolt J, van der Spoel P, Elstrodt F, et al. (2009) Antiepithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells. J Natl Cancer Inst 101: 61-66
29. Korch C, Spillman MA, Jackson TA, Jacobsen BM, Murphy SK, et al. (2012) DNA profiling analysis of endometrial and ovarian cell lines reveals misidentification, redundancy and contamination. Gynecol Oncol 127: 241-248
30. Capes-Davis A, Freshney I ( 9/ 03/2012) Database of Cross-Contaminated or Misidentified Cell Lines (Version 6.8)
31. Anglesio MS, Wiegand KC, Melnyk N, Chow C, Salamanca C, et al. (2013) Type-specific cell line models for type-specific ovarian cancer research. PLoS One 8: e72162
32. Fogh J, Fogh JM, Orfeo T (1977) One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. J Natl Cancer Inst 59: 221-226
33. Hills CA, Kelland LR, Abel G, Siracky J, Wilson AP, et al. (1989) Biological properties of ten human ovarian carcinoma cell lines: calibration in vitro against four platinum complexes. Br J Cancer 59: 527-534
34. Mackillop WJ, Trent JM, Stewart SS, Buick RN (1983) Tumor progression studied by analysis of cellular features of serial ascitic ovarian carcinoma tumors. Cancer Res 43: 874-878
35. Buick RN, Pullano R, Trent JM (1985) Comparative properties of five human ovarian adenocarcinoma cell lines. Cancer Res 45: 3668-3676
36. Boocock CA, Charnock-Jones DS, Sharkey AM, McLaren J, Barker PJ, et al. (1995) Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma. J Natl Cancer Inst 87: 506-516
37. Hamilton TC, Young RC, Ozols RF (1984) Experimental model systems of ovarian cancer: Applications to the design and evaluation of new treatment approaches. Seminars in Oncology 11: 285-298
38. Hamilton TC, Young RC, McKoy WM, Grotzinger KR, Green JA, et al. (1983) Characterization of a human ovarian carcinoma cell line (NIH: OVCAR-3) with androgen and estrogen receptors. Cancer research 43: 5379-5389
39. Marth C, Cronauer MV, Doppler W, Ofner D, Ullrich A, et al. (1992) Effects of interferons on the expression of the proto-oncogene HER-2 in human ovarian carcinoma cells. Int J Cancer 50: 64-68
40. Lounis H, Mes-Masson AM, Dion F, Bradley WE, Seymour RJ, et al. (1998) Mapping of chromosome 3p deletions in human epithelial ovarian tumors. Oncogene 17: 2359-2365
41. Provencher DM, Lounis H, Champoux L, Tetrault M, Manderson EN, et al. (2000) Characterization of four novel epithelial ovarian cancer cell lines. In Vitro Cell Dev Biol Anim 36: 357-361
42. Freedman RS, Pihl E, Kusyk C, Gallager HS, Rutledge F (1978) Characterization of an ovarian carcinoma cell line. Cancer 42: 2352-2359
43. Wilson AP, Dent M, Pejovic T, Hubbold L, Radford H (1996) Characterisation of seven human ovarian tumour cell lines. Br J Cancer 74: 722-727
44. Wilson AP (1984) Characterization of a cell line derived from the ascites of a patient with papillary serous cystadenocarcinoma of the ovary. J Natl Cancer Inst 72: 513-521
45. Kuppen PJ, Schuitemaker H, van 't Veer LJ, de Bruijn EA, van Oosterom AT, et al. (1988) cis-diamminedichloroplatinum(II)-resistant sublines derived from two human ovarian tumor cell lines. Cancer Res 48: 3355-3359
46. van den Berg-Bakker CA, Hagemeijer A, Franken-Postma EM, Smit VT, Kuppen PJ, et al. (1993) Establishment and characterization of 7 ovarian carcinoma cell lines and one granulosa tumor cell line: growth features and cytogenetics. Int J Cancer 53: 613-620
47. Karlan BY, Amin W, Band V, Zurawski VR Jr, Littlefield BA (1988) Plasminogen activator secretion by established lines of human ovarian carcinoma cells in vitro. Gynecol Oncol 31: 103-112
48. Lau DH, Lewis AD, Ehsan MN, Sikic BI (1991) Multifactorial mechanisms associated with broad cross-resistance of ovarian carcinoma cells selected by cyanomorpholino doxorubicin. Cancer Res 51: 5181-5187
49. Lau DH, Ross KL, Sikic BI (1990) Paradoxical increase in DNA cross-linking in a human ovarian carcinoma cell line resistant to cyanomorpholino doxorubicin. Cancer Res 50: 4056-4060
50. Wolf CR, Hayward IP, Lawrie SS, Buckton K, McIntyre MA, et al. (1987) Cellular heterogeneity and drug resistance in two ovarian adenocarcinoma cell lines derived from a single patient. Int J Cancer 39: 695-702
51. Langdon SP, Lawrie SS, Hay FG, Hawkes MM, McDonald A, et al. (1988) Characterization and properties of nine human ovarian adenocarcinoma cell lines. Cancer Res 48: 6166-6172
52. DelloRusso C, Welcsh PL, Wang W, Garcia RL, King MC, et al. (2007) Functional characterization of a novel BRCA1-null ovarian cancer cell line in response to ionizing radiation. Mol Cancer Res 5: 35-45
53. Benard J, Da Silva J, De Blois MC, Boyer P, Duvillard P, et al. (1985) Characterization of a human ovarian adenocarcinoma line, IGROV1, in tissue culture and in nude mice. Cancer Res 45: 4970-4979
54. Helleman J, van Staveren IL, Dinjens WN, van Kuijk PF, Ritstier K, et al. (2006) Mismatch repair and treatment resistance in ovarian cancer. BMC Cancer 6: 201
55. Nijman IJ, van Montfrans JM, Hoogstraat M, Boes ML, van de Corput L, et al. (2013) Targeted next-generation sequencing: A novel diagnostic tool for primary immunodeficiencies. J Allergy Clin Immunol
56. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, et al. (2013) Cancer genome landscapes. Science 339: 1546-1558
57. Domcke S, Sinha R, Levine DA, Sander C, Schultz N (2013) Evaluating cell lines as tumour models by comparison of genomic profiles. Nat Commun 4: 2126
58. Hollestelle A, Elstrodt F, Timmermans M, Sieuwerts AM, Klijn JG, et al. (2010) Four human breast cancer cell lines with biallelic inactivating alpha-catenin gene mutations. Breast Cancer Res Treat 122: 125-133
59. Qi W, Zhao C, Zhao L, Liu N, Li X, et al. (2014) Sorting and identification of side population cells in the human cervical cancer cell line HeLa. Cancer Cell Int 14: 3
60. Schmuck R, Warneke V, Behrens HM, Simon E, Weichert W, et al. (2011) Genotypic and phenotypic characterization of side population of gastric cancer cell lines. Am J Pathol 178: 1792-1804
61. Taddei ML, Parri M, Angelucci A, Bianchini F, Marconi C, et al. (2011) EphA2 induces metastatic growth regulating amoeboid motility and clonogenic potential in prostate carcinoma cells. Mol Cancer Res 9: 149-160
62. de Toledo M, Anguille C, Roger L, Roux P, Gadea G (2012) Cooperative antiinvasive effect of Cdc42/Rac1 activation and ROCK inhibition in SW620 colorectal cancer cells with elevated blebbing activity. PLoS One 7: e48344
63. Vega FM, Colomba A, Reymond N, Thomas M, Ridley AJ (2012) RhoB regulates cell migration through altered focal adhesion dynamics. Open Biol 2: 120076
64. Saito K, Ozawa Y, Hibino K, Ohta Y (2012) FilGAP, a Rho/Rho-associated protein kinase-regulated GTPase-activating protein for Rac, controls tumor cell migration. Mol Biol Cell 23: 4739-4750
65. Wang Y, Moncayo G, Morin P Jr, Xue G, Grzmil M, et al. (2013) Mer receptor tyrosine kinase promotes invasion and survival in glioblastoma multiforme. Oncogene 32: 872-882
66. Zheng HX, Cai YD, Wang YD, Cui XB, Xie TT, et al. (2013) Fas signaling promotes motility and metastasis through epithelial-mesenchymal transition in gastrointestinal cancer. Oncogene 32: 1183-1192
67. Hollestelle A, Peeters JK, Smid M, Timmermans M, Verhoog LC, et al. (2013) Loss of E-cadherin is not a necessity for epithelial to mesenchymal transition in human breast cancer. Breast Cancer Res Treat 138: 47-57
68. Zhang X, Liu G, Kang Y, Dong Z, Qian Q, et al. (2013) N-cadherin expression is associated with acquisition of EMT phenotype and with enhanced invasion in erlotinib-resistant lung cancer cell lines. PLoS One 8: e57692
69. Gupta N, Xu Z, El-Sehemy A, Steed H, Fu Y (2013) Notch3 induces epithelialmesenchymal transition and attenuates carboplatin-induced apoptosis in ovarian cancer cells. Gynecol Oncol 130: 200-206
70. Lo HW, Hsu SC, Xia W, Cao X, Shih JY, et al. (2007) Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial-mesenchymal transition in cancer cells via up-regulation of TWIST gene expression. Cancer Res 67: 9066-9076
71. Hynes RO, Naba A (2012) Overview of the matrisome-an inventory of extracellular matrix constituents and functions. Cold Spring Harb Perspect Biol 4: A004903
72. Naba A, Clauser KR, Hoersch S, Liu H, Carr SA, et al. (2012) The matrisome: in silico definition and in vivo characterization by proteomics of normal and tumor extracellular matrices. Mol Cell Proteomics 11: M111 014647
73. lab TH (2012) The matrisome project. Massachusetts Institute of Technology
74. Verhaak RG, Tamayo P, Yang JY, Hubbard D, Zhang H, et al. (2013) Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J Clin Invest 123: 517-525
75. Paulsson J, Micke P (2014) Prognostic relevance of cancer associated fibroblasts in human cancer. Semin Cancer Biol
76. Erkan M, Hausmann S, Michalski CW, Fingerle AA, Dobritz M, et al. (2012) The role of stroma in pancreatic cancer: diagnostic and therapeutic implications. Nat Rev Gastroenterol Hepatol 9: 454-467
77. Wood SL, Pernemalm M, Crosbie PA, Whetton AD (2014) The role of the tumor-microenvironment in lung cancer-metastasis and its relationship to potential therapeutic targets. Cancer Treat Rev 40: 558-566
78. Correia AL, Bissell MJ (2012) The tumor microenvironment is a dominant force in multidrug resistance. Drug Resist Updat 15: 39-49
79. Helleman J, Smid M, Jansen MP, van der Burg ME, Berns EM (2010) Pathway analysis of gene lists associated with platinum-based chemotherapy resistance in ovarian cancer: the big picture. Gynecol Oncol 117: 170-176
80. Jansen MP, Foekens JA, van Staveren IL, Dirkzwager-Kiel MM, Ritstier K, et al. (2005) Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling. J Clin Oncol 23: 732-740
81. Helleman J, Jansen MP, Ruigrok-Ritstier K, van Staveren IL, Look MP, et al. (2008) Association of an extracellular matrix gene cluster with breast cancer prognosis and endocrine therapy response. Clin Cancer Res 14: 5555-5564
82. Helleman J, Jansen MP, Burger C, van der Burg ME, Berns EM (2010) Integrated genomics of chemotherapy resistant ovarian cancer: A role for extracellular matrix, TGFbeta and regulating microRNAs. Int J Biochem Cell Biol 42: 25-30
83. Zoller M (2011) CD44: can a cancer-initiating cell profit from an abundantly expressed molecule? Nat Rev Cancer 11: 254-267
84. Meng E, Long B, Sullivan P, McClellan S, Finan MA, et al. (2012) CD44+/ CD24- ovarian cancer cells demonstrate cancer stem cell properties and correlate to survival. Clin Exp Metastasis 29: 939-948
85. Bapat SA, Mali AM, Koppikar CB, Kurrey NK (2005) Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer. Cancer Res 65: 3025-3029
86. Alvero AB, Chen R, Fu HH, Montagna M, Schwartz PE, et al. (2009) Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance. Cell Cycle 8: 158-166
87. Steg AD, Bevis KS, Katre AA, Ziebarth A, Dobbin ZC, et al. (2012) Stem cell pathways contribute to clinical chemoresistance in ovarian cancer. Clin Cancer Res 18: 869-881
88. Latifi A, Abubaker K, Castrechini N, Ward AC, Liongue C, et al. (2011) Cisplatin treatment of primary and metastatic epithelial ovarian carcinomas generates residual cells with mesenchymal stem cell-like profile. J Cell Biochem 112: 2850-2864
89. Auzenne E, Ghosh SC, Khodadadian M, Rivera B, Farquhar D, et al. (2007) Hyaluronic acid-paclitaxel: Antitumor efficacy against CD44(+) human ovarian carcinoma xenografts. Neoplasia 9: 479-486
90. De Stefano I, Battaglia A, Zannoni GF, Prisco MG, Fattorossi A, et al. (2011) Hyaluronic acid-paclitaxel: effects of intraperitoneal administration against CD44(+) human ovarian cancer xenografts. Cancer Chemother Pharmacol 68: 107-116